Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Emily Singer

A View from Emily Singer

More Trouble for Sirtris

A clinical trial of its drug for combating the afflictions of aging has been suspended.

  • May 5, 2010

A clinical trial of Sirtris’s drug, SRT501, a potent version of resveratrol, a molecule found in red wine, has been suspended for safety reasons. The company, which was acquired by GlaxoSmithKline two years ago, is developing a number of drugs to combat the diseases of aging. The suspended trial was testing the drug for treatment of multiple myeloma, a blood cancer, in combination with Velcade, a drug that is already on the market.

According to Bloomberg:

Five of 24 patients in the trial developed cast nephropathy, a type of kidney damage that can stem from multiple myeloma and lead to organ failure, said Jo Revill, a spokeswoman for the London-based drugmaker.

However, SRT501 has previously been tested in two other trials for type 2 diabetes, without signs of this complication. It is in development for a number of diseases, including Alzheimer’s disease, obesity, and cancer.

A separate class of molecules under development at Sirtris, has also come under fire recently. These molecules, known as sirtuin activators, were named for their reported ability to activate SIRT1, an enzyme thought to play a crucial role in aging. As I noted in a previous blog,

The Pfizer study suggested that resveratrol, a compound found in red wine, and other molecules under development at Sirtris, don’t really activate this key enzyme and may not even have the life-extending benefits that have been reported by Sirtris founder David Sinclair and others.

Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.

Subscribe today

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Premium.
  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look: exclusive early access to important stories, before they’re available to anyone else

    Insider Conversations: listen in on in-depth calls between our editors and today’s thought leaders

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.